By Fineline Cube 
Suzhou-based Medilink Therapeutics announced a clinical study collaboration agreement with Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (Wuhan Union Hospital). This partnership aims to enhance clinical development capabilities and accelerate the progression of Medilink’s therapeutic programs.
Collaboration Details
The two parties have established extensive clinical development ties, with 8 ongoing registration-directed clinical trials spanning 7 therapeutic areas: breast cancer, lung cancer, esophageal cancer, prostate cancer, nasopharyngeal cancer, head and neck squamous cell carcinoma, and ovarian cancer. This comprehensive collaboration leverages the expertise and resources of both organizations to advance medical research and innovation.
Wuhan Union Hospital’s Role
Wuhan Union Hospital will provide specialized investigators and resources to support Medilink’s clinical programs. The hospital’s involvement is expected to significantly speed up the clinical trial process. By integrating resources across pharmaceuticals, healthcare, and digital technologies, the collaboration aims to enable data-driven trial design, foster shared innovation ecosystems, and ensure efficient project execution.-Fineline Info & Tech